The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

GSK (GB0009252882) remains a diversified big pharma player on the NYSE, with investors watching how its vaccines and specialty medicines strategy translates into earnings over the next few years.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

FDA expands GSK's Arexvy RSV vaccine to adults 18-49 at risk, opening a market of ~21M. GSK also advances liver disease pipeline and buybacks. GSK Secures Key FDA Approval to Expand RSV Vaccine Market ...

GSK is taking to the airwaves to get the message out about respiratory syncytial virus (RSV), presenting a TV special about how the pathogen has affected athletes in the upcoming National Senior Games ...

GSK (GSK) announced on Friday that the U.S. Food and Drug Administration (FDA) has approved a label expansion for its Arexvy vaccine against the Respiratory Syncytial Virus (RSV) to allow its use for ...

GSK plc GSK announced that the FDA approved the expanded use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine, Arexvy, in adults aged 18 to 49 years who are at a higher risk of ...

In the US, an estimated 21 million adults under 50 have at least one risk factor for severe RSV infection 1 * PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food ...

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new effectiveness data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) at RSVVW’26, the 9th Conference of the ...

GSK plc GSK announced that the FDA has accepted its regulatory filing seeking to expand the use of its RSV vaccine, Arexvy, in adults under 50 who are at a higher risk of the disease. A final decision ...